These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32046452)

  • 21. Comparison of scales for evaluating premenstrual symptoms in women using oral contraceptives.
    Coffee AL; Kuehl TJ; Sulak PJ
    Pharmacotherapy; 2008 May; 28(5):576-83. PubMed ID: 18447656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of premenstrual dysphoria with continuous versus intermittent dosing of oral contraceptives: Results of a three-arm randomized controlled trial.
    Eisenlohr-Moul TA; Girdler SS; Johnson JL; Schmidt PJ; Rubinow DR
    Depress Anxiety; 2017 Oct; 34(10):908-917. PubMed ID: 28715852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of combined oral contraception containing drospirenone on premenstrual exacerbation of Meniere's disease: Preliminary study.
    Caruso S; Mauro D; Maiolino L; Grillo C; Rapisarda AMC; Cianci S
    Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():102-107. PubMed ID: 29573626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study.
    Wood SH; Mortola JF; Chan YF; Moossazadeh F; Yen SS
    Obstet Gynecol; 1992 Sep; 80(3 Pt 1):339-44. PubMed ID: 1495689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: II. Clinical effects.
    Zimmerman Y; Foidart JM; Pintiaux A; Minon JM; Fauser BC; Cobey K; Coelingh Bennink HJ
    Contraception; 2015 Feb; 91(2):134-42. PubMed ID: 25496917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluoxetine in the treatment of premenstrual syndrome.
    Ozeren S; Corakçi A; Yücesoy I; Mercan R; Erhan G
    Eur J Obstet Gynecol Reprod Biol; 1997 Jun; 73(2):167-70. PubMed ID: 9228499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.
    Fenton C; Wellington K; Moen MD; Robinson DM
    Drugs; 2007; 67(12):1749-65. PubMed ID: 17683173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial.
    Miner C; Brown E; McCray S; Gonzales J; Wohlreich M
    Clin Ther; 2002 Mar; 24(3):417-33. PubMed ID: 11952025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drospirenone: a novel progestin.
    Rapkin AJ; Winer SA
    Expert Opin Pharmacother; 2007 May; 8(7):989-99. PubMed ID: 17472544
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle-A double-blind, placebo-controlled randomized trial.
    Lundin C; Danielsson KG; Bixo M; Moby L; Bengtsdotter H; Jawad I; Marions L; Brynhildsen J; Malmborg A; Lindh I; Sundström Poromaa I
    Psychoneuroendocrinology; 2017 Feb; 76():135-143. PubMed ID: 27923181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maintaining physiological testosterone levels by adding dehydroepiandrosterone to combined oral contraceptives: I. Endocrine effects.
    Coelingh Bennink HJT; Zimmerman Y; Laan E; Termeer HMM; Appels N; Albert A; Fauser BCJM; Thijssen JHH; van Lunsen RHW
    Contraception; 2017 Nov; 96(5):322-329. PubMed ID: 27393080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A double-blind trial of four medications to treat severe premenstrual syndrome.
    Diegoli MS; da Fonseca AM; Diegoli CA; Pinotti JA
    Int J Gynaecol Obstet; 1998 Jul; 62(1):63-7. PubMed ID: 9722128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hormonal therapy in the management of premenstrual syndrome.
    Tiemstra JD; Patel K
    J Am Board Fam Pract; 1998; 11(5):378-81. PubMed ID: 9796767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. YAZ in the treatment of premenstrual dysphoric disorder.
    Rapkin AJ
    J Reprod Med; 2008 Sep; 53(9 Suppl):729-41. PubMed ID: 18980045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of the combined oral contraceptive ethinylestradiol/drospirenone (Yasmin) in healthy Chinese women: a randomized, open-label, controlled, multicentre trial.
    Guang-Sheng F; Mei-Lu B; Li-Nan C; Xiao-Ming C; Zi-Rong H; Zi-Yan H; Xiao-Ping J; Jian L; Shu-Ying W; Cheng-Liang X; Zheng-Ai X; Tian-Fu Y
    Clin Drug Investig; 2010; 30(6):387-96. PubMed ID: 20201608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms.
    Brown C; Ling F; Wan J
    J Reprod Med; 2002 Jan; 47(1):14-22. PubMed ID: 11838304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drospirenone-containing combined oral contraceptives and the risk of arterial thrombosis: a population-based nested case-control study.
    Larivée N; Suissa S; Eberg M; Joseph L; Eisenberg MJ; Abenhaim HA; Filion KB
    BJOG; 2017 Oct; 124(11):1672-1679. PubMed ID: 27704723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen.
    Marr J; Niknian M; Shulman LP; Lynen R
    Contraception; 2011 Jul; 84(1):81-6. PubMed ID: 21664515
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: I. Endocrine effects.
    Zimmerman Y; Foidart JM; Pintiaux A; Minon JM; Fauser BC; Cobey K; Coelingh Bennink HJ
    Contraception; 2015 Feb; 91(2):127-33. PubMed ID: 25604900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
    Koltun W; Lucky AW; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
    Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.